White Rose Research Online

eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk
Universities of Leeds, Sheffield and York

Deposited via The University of Leeds.

White Rose Research Online URL for this paper:
https://eprints.whiterose.ac.uk/id/eprint/116583/

Version: Supplemental Material

Article:
Mackie, SL, Twohig, H, Neill, LM et al. (2017) The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica. Journal of Rheumatology, 44 (10). 161109. pp. 1515-1521. ISSN: 0315-162X

https://doi.org/10.3899/jrheum.161109

© 2017 The Journal of Rheumatology. This is a pre-copy-editing, author-produced PDF of an article accepted for publication in The Journal of Rheumatology following peer review. The definitive publisher-authenticated version, Mackie, et al. (2017) The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica. Journal of Rheumatology, 44. 161109, is available online at: https://doi.org/10.3899/jrheum.161109.

Reuse
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

Table 2. Results from Rounds 1 and 2 of Delphi study of core domains for polymyalgia rheumatica.

Domain	Round 1 Clinicians (n=60), %	Round 1 Patients (n=55), %	Round 2 Clinicians (n=55), %	Round 2 Patients (n=46), %
Pain/ache	**90**	**78**	-	-
Stiffness severity	56	56	53	**74**
Morning stiffness duration	68	36	**85**	43
Muscle weakness	12	53	-	**80**
Fatigue / tiredness	49	**73**	65	-
Sleep disturbance	10	35	-	57
Mood problems – low or "high"	3	20	-	37
Anxiety	3	33	-	30
Weight loss/gain	25	33	27	48
Appetite loss/gain	3	11	-	-
Balance problems	2	7	-	-
Fevers/shivers/sweats/flu like symptoms	12	15	-	-
Ability to do everyday activities	51	55	65	**74**
Lack of mobility	25	35	7	59
Dependence on stick, wheelchair, etc.	0	2	-	-
Dependence on other people	5	9	-	-
Ability to carry out usual roles (work, caring for others, etc.)	20	35	16	37
Health-related quality of life	50	24	76	39
Overall quality of life	27	51	13	**72**
Change in appearance of face or body	8	22	-	41
Fluid retention / ankle swelling	2	9	-	-
Bruising, poor healing or other skin change	5	24	-	50
Doctor's assessment of activity/severity of PMR	59	60	**71**	83
Patient's assessment of activity/severity of PMR	**76**	42	-	**76**
Blood tests	**86**	40	-	**70**
Abnormalities identified by physical examination	22	7	20	-

by a doctor				
Abnormalities identified by imaging tests	36	20	29	33
Bone fragility	27	13	29	-
New or worsening diabetes mellitus	14	5	-	-
High blood pressure	12	11	-	-
Cost of treatments used in the study	31	18	13	-
Overall costs to the healthcare provider	36	24	22	11
Overall costs to society	56	40	55	20
Any glucocorticoid-related adverse effect in judgement of doctor	-	-	46	63
Any glucocorticoid-related adverse effect in judgement of patient	-	-	23	80

Numbers given are percentages of respondents selecting each outcome. Domains with >70% agreement are highlighted in bold;, for each group (clinicians or patients) only domains with 20-69% agreement in round 1 went forward to Round 2. Bold denotes that with >70% agreement from either group in Round 1 or Round 2, the domain went forward into the combined Round 3. "-" denotes that the question was not asked in that round.
PMR: polymyalgia rheumatica